Patents by Inventor M. W. Visseren

M. W. Visseren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated tumor rejection antigen precursor mage-2 derived peptides and uses thereof
    Patent number: 6147187
    Abstract: The invention describes peptides derived from tumor rejection antigen precursor MAGE-2. These peptides bind with HLA-A2 molecules, thus presenting complexes which provoke cytolytic T cell production. The resulting "CTLs" are specific for complexes of HLA-A2 and the peptide. The complexes can be used to generate monoclonal antibodies. The cytolytic T cells produced may be used in the context of immunotherapy, such as adoptive transfer.
    Type: Grant
    Filed: January 15, 1998
    Date of Patent: November 14, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Cornelis J. M. Melief, M. W. Visseren, W. M. Kast, Pierre van der Bruggen, Thierry Boon-Falleur
  • Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
    Patent number: 5686068
    Abstract: New peptides derived from the MAGE-2 molecule and which bind to HLA-A*0201 molecules are disclosed. Some of these are especially useful because, when complexed to their HLA-A*0201 partner molecules, they induce CTL proliferation.
    Type: Grant
    Filed: July 25, 1996
    Date of Patent: November 11, 1997
    Assignees: Ludwig Institute for Cancer Research, Leiden University
    Inventors: Cornelius J. M. Melief, M. W. Visseren, Sjoerd van der Burg, Pierre van der Bruggen, Thierry Boon-Falleur